Ann: US FDA Completes Review of IHL-42x IND Application, page-66

Data Analysis Milestones:
If the trial includes predefined data analysis milestones (such as interim analyses), the IRB may conduct reviews around these milestones to assess the emerging data.

It has been reported at the Sydney S/H Meeting - IHL-42X Phase 2/3 Trial
"52-week trial with interim updates to the market at 3, 6, and 12 months"
https://hotcopper.com.au/threads/sydney-meeting.7543568/

Assuming - November 2023 Start;
Interim analysis February, May, November 2024.

I assume these milestones will be part of the motivation for the re-domicile to the USA; (in November)
to release these results to the broader USA market starting in February

The question for me will be if it is a Phase 2/3 over 12 months when does it evolve from Phase 2 to Phase 3

Good luck @bpotter78